Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Markets

Clear Street starts LB Pharmaceuticals at buy; PT $45

Clear Street initiated coverage of LB Pharmaceuticals (NASDAQ: LBRX) with a “buy” rating and price target of $45.00. The stock closed at $28.33 on May 26th. LB Pharmaceuticals is a late-stage biopharmaceutical company...

May 26, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Developments

Assembly broadens program into cholestatic liver diseases

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary...

May 22, 2026

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Developments

Adagio submits PMA for vCLAS Ventricular Ablation System for VT

Adagio Medical Holdings (NASDAQ: ADGM) has announced the submission of its Premarket Approval (PMA) application to the FDA for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent...

May 21, 2026

Developments

Medtronic to buy SPR Therapeutics for ~$650 million

Medtronic (NYSE: MDT) announced its intent to acquire SPR Therapeutics, a closely held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for...

May 20, 2026

Developments

Envoy expands IP portfolio with new patents in fully implanted hearing technology

Envoy Medical (NASDAQ: COCH) has announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the company’s intellectual...

May 20, 2026

Developments

CRC approves Cohort 2 opening of nimacimab expansion study

Skye Biosciences (NASDAQ: SKYE) has announced that the Cohort Review Committee (CRC) has approved opening the second cohort of the CBeyond Part C Expansion study of nimacimab in obesity, based on favorable safety data...

May 20, 2026

Developments

PharmaJet spotlights review in Qeios listing advantages of needle-free ID delivery v. traditional needle and syringe

Closely held PharmaJet has highlighted a peer-reviewed publication in the AI-powered open science publishing platform Qeios, which evaluated the evidence on implementation of novel technologies for intradermal (ID)...

May 19, 2026

Subscribe